

Major genetic marker of nidoviruses encodes a replicative endoribonuclease

Konstantin A. Ivanov*, Tobias Hertzig*, Mikhail Rozanov†, Sonja Bayer*, Volker Thiel‡, Alexander E. Gorbalenya§, and John Ziebuhr*¶

*Institute of Virology and Immunology, University of Würzburg, 97078 Würzburg, Germany; †National Center for Biotechnology Information, National Institutes of Health, Bethesda, MD 20894; ‡Research Department, Cantonal Hospital, CH-9007 St. Gallen, Switzerland; and §Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands

Edited by Peter K. Vogt, The Scripps Research Institute, La Jolla, CA, and approved July 9, 2004 (received for review May 4, 2004)

Coronaviruses are important pathogens that cause acute respiratory diseases in humans. Replication of the ≈30-kb positive-strand RNA genome of coronaviruses and discontinuous synthesis of an extensive set of subgenome-length RNAs (transcription) are mediated by the replicase–transcriptase, a barely characterized protein complex that comprises several cellular proteins and up to 16 viral subunits. The coronavirus replicase–transcriptase was recently predicted to contain RNA-processing enzymes that are extremely rare or absent in other RNA viruses. Here, we established and characterized the activity of one of these enzymes, replicative nidoviral uridylylate-specific endoribonuclease (NendoU). It is considered a major genetic marker that discriminates nidoviruses (*Coronaviridae*, *Arteriviridae*, and *Roniviridae*) from all other RNA virus families. Bacterially expressed forms of NendoU of severe acute respiratory syndrome coronavirus and human coronavirus 229E were revealed to cleave single-stranded and double-stranded RNA in a Mn²⁺-dependent manner. Single-stranded RNA was cleaved less specifically and effectively, suggesting that double-stranded RNA is the biologically relevant NendoU substrate. Double-stranded RNA substrates were cleaved upstream and downstream of uridylylates at GUU or GU sequences to produce molecules with 2′-3′ cyclic phosphate ends. 2′-O-ribose-methylated RNA substrates proved to be resistant to cleavage by NendoU, indicating a functional link with the 2′-O-ribose methyltransferase located adjacent to NendoU in the coronavirus replicative polyprotein. A mutagenesis study verified potential active-site residues and allowed us to inactivate NendoU in the full-length human coronavirus 229E clone. Substitution of D6408 by Ala was shown to abolish viral RNA synthesis, demonstrating that NendoU has critical functions in viral replication and transcription.

Human coronavirus 229E (HCoV-229E), a group 1 coronavirus, is one of the major viral pathogens causing upper respiratory tract illness in humans (1), whereas severe acute respiratory syndrome coronavirus (SARS-CoV), a group 2 coronavirus, has been identified as the causative agent of SARS, a life-threatening form of pneumonia that caused >8,000 fatalities in a worldwide epidemic in 2003 (2, 3). The extremely large positive-strand RNA genomes of HCoV-229E (27.3 kb) and SARS-CoV (29.7 kb) contain 8 and 14 ORFs, respectively (4, 5). The two most 5′-terminal ORFs, 1a and 1b, encode the major subunits of the replicative machinery, whereas the more downstream ORFs encode structural and virus-specific accessory proteins.

Coronavirus gene expression involves a series of complex transcriptional, translational, and posttranslational regulatory mechanisms (6, 7). After receptor-mediated entry, two large replicative polyproteins, pp1a (>450 kDa) and pp1ab (>750 kDa), are translated from the genome RNA. The polyproteins are encoded by the replicase gene (>20,000 bases) that comprise ORFs 1a and 1b (Fig. 1A) (8). Expression of pp1ab involves ribosomal frameshifting into the −1 frame just upstream of the ORF 1a translation termination codon (9). Human coronavirus polyproteins are autoproteolytically processed by two (SARS-




Fig. 1. Human coronavirus replicase genes encode a putative endoribonuclease. (A) Functional ORFs in the genomes of SARS-CoV and HCoV-229E are expressed from both genomic RNA and a set of subgenomic mRNAs. ORFs encoding the four structural proteins S, E, M, and N, are indicated in black. The ORF 1a- and ORF 1b-encoded proteins, pp1a and pp1ab, are cleaved by viral proteases to yield 16 processing end-products: nsp1–nsp16. The C-terminal part of nsp15 was predicted to harbor an endoribonuclease domain (20). (B) Partial sequence alignment of SARS-CoV and HCoV-229E NendoU domains with *Xenopus laevis* XendoU, a poly(U)-specific endoribonuclease. Conserved residues targeted in this study by site-directed mutagenesis are indicated by filled (HCoV-229E) and open (SARS-CoV) arrows.

CoV) or three (HCoV-229E) viral proteases called papain-like proteases and 3C-like main protease (5, 10–12). In total, at least 16 processing end-products called nonstructural proteins (nsp) 1–16 are derived from the pp1a and pp1ab polyproteins (8).

This paper was submitted directly (Track II) to the PNAS office.

Freely available online through the PNAS open access option.

Abbreviations: ds, double-stranded; ss, single-stranded; HCoV-229E, human coronavirus 229E; MBP, *Escherichia coli* maltose-binding protein; NendoU, nidoviral uridylylate-specific endoribonuclease; nsp, nonstructural protein; SARS-CoV, severe acute respiratory syndrome coronavirus; PNK, T4 polynucleotide kinase; CIP, calf intestine phosphatase; TRS, transcription-regulating sequence; XendoU, *Xenopus laevis* poly(U)-specific endoribonuclease.

¶To whom correspondence should be addressed at: Institute of Virology and Immunology, Versbacher Strasse 7, 97078 Würzburg, Germany. E-mail: j.ziebuhr@mail.uni-wuerzburg.de.

© 2004 by The National Academy of Sciences of the USA

Together with a number of processing intermediates and cellular proteins, nsp1–nsp16 are thought to form a huge membrane-anchored protein complex, called replicase–transcriptase, that is poorly characterized but generally accepted to mediate all of the functions required for genome replication and synthesis of a diverse set of subgenomic mRNAs (transcription) (13). Coronavirus subgenomic mRNAs have a common 5'-terminal leader sequence that is identical to the 5' end of the genome, which are produced through a unique discontinuous transcription mechanism (14, 15).

Besides a putative RNA-dependent RNA polymerase activity (16) and the previously characterized helicase and protease activities (7, 17–19), which are all common to positive-strand RNA viruses, the coronavirus replicase–transcriptase also contains a set of putative enzymes that are rare or even unique among other RNA viruses. Thus, nsp3, nsp14, nsp15, and nsp16 were recently predicted to harbor ADP-ribose 1"-phosphatase, 3'-to-5' exoribonuclease, endoribonuclease, and 2'-O-ribose methyltransferase domains (20). It seems logical to link the conservation of these additional and, in part, unique activities with the enormous size of the coronavirus RNA genome and the unusual RNA synthesis mechanisms used by coronaviruses (20). To a varying degree, the putative coronavirus RNA-processing activities are also conserved in distant relatives from the *Nidovirales* order that use similar RNA synthesis mechanisms and/or have comparably large genomes (20).

We initiated a broad analysis of these newly predicted enzymes by using HCoV-229E and SARS-CoV. In this paper, we describe the characterization of nsp15, which has been predicted to contain in its C-terminal region a nidovirus-wide conserved endoribonuclease domain called nidoviral uridylylate-specific endoribonuclease (NendoU) (20). We show by site-directed mutagenesis of the nsp15 coding sequence in the infectious HCoV-229E clone that the domain is critically involved in coronavirus replication and transcription. Recombinant forms of both HCoV-229E and SARS-CoV nsp15 were revealed to possess Mn²⁺-dependent endoribonuclease activities that produce molecules with 2'-3' cyclic phosphate ends. The data suggest a preference of NendoU for cleavage of double-stranded (ds)RNA substrates upstream and downstream of uridylylates in GU or GUU sequences. RNA 2'-O-ribose methylation blocked these cleavages, indicating a functional link between the coronavirus NendoU and putative 2'-O-ribose methyltransferase activities. The coordinated expression of the NendoU and 2'-O-ribose methyltransferase activities, which reside adjacent to each other in the viral polyprotein in nsp15 and nsp16, further supports a functional interplay between these activities. Finally, the characterization of nsp15 mutants with substitutions of conserved residues allowed insights into the active site of this endoribonuclease family.

Materials and Methods

Protein Expression and Purification. Nucleotides 19,551–20,588 of SARS-CoV (strain Frankfurt 1) and 18,622–19,665 of HCoV-229E, respectively, followed by a translation stop codon, were inserted in the unique *Xmn*I site of pMal-c2 plasmid DNA (New England Biolabs). Mutations in the nsp15 coding sequence were introduced by PCR-based methods. For protein expression, pMal-SARS-CoV-nsp15 and pMal-HCoV-229E-nsp15 plasmid DNA, respectively, or mutant derivatives were used to transform *Escherichia coli* TB1 cells (New England Biolabs). Maltose-binding protein (MBP) fusion proteins were expressed and purified by amylose affinity chromatography as described in ref. 10.

RNA and DNA Substrates and Size Markers. RNA oligonucleotides were purchased from Eurogentec (Seraing, Belgium): RNA2 (5'-CGCAGUGAGCUCCUAAUCGCC-3'), RNA3 (5'-CG-

CAGUUAGCUCCUAAUCGCC-3'), RNA8 (5'-GGGC-GAUUAGGAGCUAACUGCG-3'), and RNA9 (2'-O-methyl RNA3) and marker RNAs m1 (5'-CGCAGUUA-3'), m2 (5'-CGCAGUU-3'), m3 (5'-CGCAGU-3'), m4 (5'-CGCAG-3'), and m5 (5'-CGCA-3'). To produce dsRNA forms of RNAs 2, 3, and 9, the oligonucleotides were annealed with a 1.5-fold excess of RNA8. Longer RNA and DNA substrates of 1 kbp were produced by *in vitro* transcription and PCR by using the protocols described in ref. 18. We performed 5'-labeling of single-stranded (ss)DNAs and ssRNAs by using T4 polynucleotide kinase (PNK) and [γ -³²P]ATP.

Nuclease Assay. Typical reactions contained 300 nM of wild-type or mutant MBP-nsp15 and 50 nM (labeled) or 500 nM (unlabeled) (ribo)oligonucleotide. Longer DNA and RNA molecules of 1 kbp were used at 10 nM. Reactions were performed in 25 mM Hepes-KOH (pH 7.4)/50 mM NaCl/5 mM MnCl₂/1 mM DTT. Following incubation at 37°C for up to 60 min, the reactions were stopped by adding an equal volume of loading buffer (formamide containing 10 mM EDTA) and the products were analyzed in 8% or 20% polyacrylamide gels (acrylamide/bisacrylamide ratio, 19:1) buffered with 0.5× Tris-borate-EDTA containing 0.1% SDS or 7.5 M urea.

Analysis of the 3' Terminus. Gel-purified 5'-terminal cleavage product of RNA2 was incubated with (i) buffer P alone (70 mM Tris-HCl, pH 7.6/10 mM MgCl₂/5 mM DTT), (ii) buffer P in the presence of 5 units of PNK or (iii) buffer C (50 mM Tris-HCl, pH 7.9/100 mM NaCl/10 mM MgCl₂/1 mM DTT) in the presence of 5 units of calf intestine phosphatase (CIP). After incubation at 37°C for 30 min, the reaction mixtures were incubated at 94°C for 5 min. Thereafter, the RNAs were ethanol-precipitated and redissolved in 50 mM Tris-HCl, pH 7.8/10 mM MgCl₂/10 mM DTT/10% dimethyl sulfoxide/5 μM ATP/20 μg/ml BSA. The mixtures were then incubated for 3.5 h at 4°C with 8 units of T4 RNA ligase and 1 μM [5'-³²P]pCp [3,000 Ci/mmol (1 Ci = 37 GBq)] and analyzed by denaturing PAGE and autoradiography.

Primer Extension. Unlabeled dsRNAs 2 and 3, respectively, were cleaved with nsp15. The resulting products were annealed with 5'-[γ -³²P]-labeled DNA14 and DNA15, respectively, in first-strand Superscript III buffer (Invitrogen) supplemented with 5 mM DTT and 1 mM dNTPs. After incubation with 200 units of Superscript III RNase H⁻ reverse transcriptase at 40°C for 30 min, the reactions were stopped by adding equal volumes of loading buffer and the reaction products were analyzed by denaturing PAGE.

Mutagenesis of the HCoV-229E Full-Length cDNA Clone. The recombinant vaccinia virus vHCoV-inf-1 containing the full-length cDNA of HCoV-229E (21) was used to construct vHCoV-1ab-D6408A, a mutant derivative in which the HCoV-229E nucleotides ¹⁹⁵¹³GAT (encoding pp1ab residue Asp-6408) were substituted with ¹⁹⁵¹³GCT (Ala-6408). Mutagenesis of vHCoV-inf-1 involved several steps of vaccinia virus-mediated recombination by using the *E. coli* guanine phosphoribosyltransferase (*gpt*) gene as a marker for positive or negative selection (see *Supporting Materials and Methods*, which is published as supporting information on the PNAS web site). Genome-length RNA was prepared by *in vitro* transcription by using purified genomic DNA from vHCoV-inf-1 and vHCoV-1ab-D6408A, respectively. HCoV-inf-1 RNA and HCoV-1ab-D6408A RNA (15 μg), respectively, were used for electroporation of 4 × 10⁶ BHK-21 cells expressing the HCoV-229E nucleocapsid protein [BHK-21 (N) cells] (V.T., unpublished data). At 72 h after transfection, viral RNA synthesis was analyzed by Northern blotting by using a ³²P-labeled probe corresponding to HCoV-229E nucleotides 26,297–27,273.




Fig. 4. RNA 2'-O-ribose methylation blocks clearance by coronavirus nsp15. dsRNA substrates were produced by annealing RNA8 to the complementary 5'-[³²P]-labeled RNA3 or its 2'-O-ribose-methylated derivative, RNA9. Substrates were incubated with SARS-CoV (SCoV) and HCoV-229E (HCoV) MBP-nsp15, respectively, or inactive control proteins. Reaction products were analyzed by denaturing PAGE and autoradiography. Lanes 1 and 6, reactions without protein; lanes 2 and 7, reactions with HCoV-229E MBP-nsp15.H6360A; lanes 3 and 8, reactions with HCoV-229E MBP-nsp15; lanes 4 and 9, reactions with SARS-CoV MBP-nsp15.H6678A; lanes 5 and 10, reactions with SARS-CoV MBP-nsp15.

this protein in the life cycle of these viruses. To test this hypothesis, we introduced a single point mutation into the infectious HCoV-229E cDNA clone, leading to a replacement of the pp1ab residue Asp-6408 with Ala. As shown above (Fig. 6), this substitution completely inactivated the endonucleolytic activity of the MBP-nsp15 fusion protein *in vitro*. Analysis of viral RNA synthesis after transfection of mutant and wild-type RNA, respectively, into BHK-21 (N) cells revealed a complete block of viral RNA synthesis for the nsp15 mutant (Fig. 8, which is published as supporting information on the PNAS web site), demonstrating the critical role of nsp15 in coronavirus replication and transcription.

Discussion

We present here the results of the identification and characterization of an RNase of human coronaviruses designated NendoU. Besides E^{rns}, a secreted and virion-associated RNase of pestiviruses (25), NendoU is just the second group of RNases identified in the >40 families of positive-strand RNA viruses. E^{rns} was recently shown to be a pestivirus-specific cofactor of cell




Fig. 5. Coronavirus NendoU activity produces molecules with 2'-3' cyclic phosphate termini. Ligation of 5'-[³²P]pCp with the 3' terminus of coronavirus nsp15 cleavage products using T4 RNA ligase requires pretreatment with PNK that (in contrast to CIP) is capable of removing 2'-3' cyclic phosphates. Reaction products were analyzed by denaturing PAGE and autoradiography. Lane 1, ligation reaction with control RNA m4; lanes 2-4, ligation reactions with purified 5'-terminal nsp15 cleavage product without further treatment (lane 2) and after treatment with PNK (lane 3) or CIP (lane 4).




Fig. 6. Activities of mutant forms of human coronavirus NendoU. (A) Coomassie brilliant blue-stained SDS-polyacrylamide gel showing the expression and purification of HCoV-229E (HCoV) and SARS-CoV (SCoV) MBP-nsp15 fusion proteins. Lanes 1 and 2, total lysates of *E. coli* cells transformed with pMal-HCoV-nsp15 plasmid DNA and grown in the absence (lane 1) or presence (lane 2) of isopropyl β -D-thiogalactoside (IPTG); lanes 3-12, purified MBP-nsp15 fusion proteins with nsp15 wild-type sequence (WT) or with the indicated substitutions of conserved residues. Numbering of residues is according to their positions in the replicase polyproteins of HCoV-229E and SARS-CoV, respectively. (B) HCoV-229E and SARS-CoV MBP-nsp15 fusion proteins or their mutant derivatives were incubated with dsRNA2, and reaction products were separated in a 20% polyacrylamide gel containing 7.5 M urea.

entry; it is not encoded in the related hepaciviruses and flaviviruses. In contrast, NendoU belongs to the few replicative domains conserved in coronaviruses and all their distant nidovirus relatives (*Arteriviridae* and *Roniviridae*) (20, 26). In fact, it is one of only two unique genetic markers common to nidoviruses but absent in other RNA viruses (26, 27). Accordingly, NendoU is expected to mediate a nidovirus-specific step in RNA synthesis. Given the need to replicate positive-strand RNA genomes of extraordinary size, the presence of a replicative endoribonuclease in nidoviruses is a surprising finding that adds yet another dimension to the amazing plasticity of RNA viruses that is commonly associated with rapid evolution.

The data on two human coronavirus NendoU revealed striking parallels to a distant cellular homolog, XendoU, a poly(U)-specific endoribonuclease involved in small nucleolar RNA processing and utilization (22). The recently proposed relationship between XendoU and NendoU (20) is strongly supported by the biochemical data obtained in this study. Thus, like their cellular homolog, NendoU depended on Mn²⁺ ions and, rather untypical for Mn²⁺-dependent nucleases, generated molecules with 2'-3' cyclic phosphate ends. Besides the similar chemistry of endonucleolytic cleavage, the cellular and viral homologs also share a similar specificity to uridylylates in both ssRNAs and dsRNAs.

We found a strong preference of NendoU for cleavage at GU(U) sequences in dsRNA, whereas corresponding ssRNA molecules were cleaved (albeit less efficiently) also at uridylylates preceded by cytidylate or adenylate residues. These observations

suggest that the biologically relevant substrate of NendoU, which remains to be identified, may be dsRNA. Although more substrates must be tested to verify the sequence preference evident in this study, the complementarity of GUU to the strictly conserved core element, AAC, of nidovirus transcription-regulating sequences (TRSs) is noteworthy. TRSs are known to play a critical role in (discontinuous) minus-strand RNA synthesis in which they guide (by complementary basepairing) the transfer of the nascent minus strand to an upstream sequence (called leader TRS) on the template RNA (14, 15, 28). It is tempting to speculate that GUU, when part of dsRNA during minus-strand synthesis, is a candidate sequence to be cleaved by NendoU (before or after transfer of the nascent minus strand to the leader TRS). If confirmed, this cleavage may be used to remove potentially nonpaired nucleotides downstream of the minus-strand TRS complement upon its binding to the leader TRS.

Regardless of whether NendoU cleaves only GU(U) or also other short sequence(s), its activity must be sufficiently controlled to achieve an appropriate selectivity in the endonucleolytic processing of natural substrates. This control may include both protein and polynucleotide factors interacting with NendoU itself or NendoU substrates. In this respect, our finding that 2'-O-ribose methyl groups rendered RNA substrates insensitive to cleavage by NendoU is of particular interest as it suggests a cooperation between nsp15, which contains the NendoU domain, and nsp16, which is predicted to be a 2'-O-ribose methyltransferase. Should this (functional) cooperation be con-

firmed, it would provide a rationale for the coordinated release of the adjacent nsp15 and nsp16 subunits from the pp1ab polyprotein by 3C-like main protease (29).

Our data also provide support for parallels between ribosomal preRNA processing pathways (involving XendoU) and nidovirus RNA synthesis (involving NendoU) (20). In this context, it should be interesting to investigate whether NendoU has cellular substrates and is used to produce small regulatory RNAs (similar to the small nucleolar RNAs produced by XendoU) that may bind to specific (viral and/or cellular) target sequences by complementary base-pairing to trigger 2'-O-ribose methylation(s) by nsp16 (or cellular methylases).

To link the fundamental and applied aspects of the NendoU study, we characterized orthologs from two human coronaviruses and found very similar biochemical properties. These data together with the nidovirus-wide conservation of NendoU, the essential role in coronavirus RNA synthesis (demonstrated here for HCoV-229E), and the lack of close cellular homologs suggest that NendoU may be an attractive target for the development of selective antiviral drugs to combat respiratory infections caused by SARS-CoV and other known or emerging human nidoviruses.

We thank Eric Snijder and Clara Posthuma (Leiden University Medical Center) for sharing unpublished data. J.Z. thanks Stuart Siddell (University of Bristol) for the recombinant vaccinia virus vHCoV-inf-1 and for contributing to the development of the HCoV-229E reverse genetics system. The work was supported by Deutsche Forschungsgemeinschaft Grants SFB 479 and Zi 618/2-3 (to J.Z.).

- Myint, S. H. (1995) in *The Coronaviridae*, ed. Siddell, S. G. (Plenum, New York), pp. 389–401.
- Peiris, J. S., Yuen, K. Y., Osterhaus, A. D. & Stöhr, K. (2003) *N. Engl. J. Med.* **349**, 2431–2441.
- Peiris, J. S., Lai, S. T., Poon, L. L., Guan, Y., Yam, L. Y., Lim, W., Nicholls, J., Yee, W. K., Yan, W. W., Cheung, M. T., et al. (2003) *Lancet* **361**, 1319–1325.
- Herold, J., Raabe, T., Schelle-Prinz, B. & Siddell, S. G. (1993) *Virology* **195**, 680–691.
- Thiel, V., Ivanov, K. A., Putics, A., Hertzog, T., Schelle, B., Bayer, S., Weissbrich, B., Snijder, E. J., Rabenau, H., Doerr, H. W., Gorbalenya, A. E. & Ziebuhr, J. (2003) *J. Gen. Virol.* **84**, 2305–2315.
- Lai, M. M. C. & Holmes, K. V. (2001) in *Fields Virology*, eds. Knipe, D. M. & Howley, P. M. (Lippincott, Philadelphia), Vol. 1, pp. 1163–1185.
- Ziebuhr, J., Snijder, E. J. & Gorbalenya, A. E. (2000) *J. Gen. Virol.* **81**, 853–879.
- Ziebuhr, J. (2004) *Curr. Top. Microbiol. Immunol.* **287**, in press.
- Brierley, I., Digard, P. & Inglis, S. C. (1989) *Cell* **57**, 537–547.
- Ziebuhr, J., Herold, J. & Siddell, S. G. (1995) *J. Virol.* **69**, 4331–4338.
- Ziebuhr, J., Thiel, V. & Gorbalenya, A. E. (2001) *J. Biol. Chem.* **276**, 33220–33232.
- Herold, J., Gorbalenya, A. E., Thiel, V., Schelle, B. & Siddell, S. G. (1998) *J. Virol.* **72**, 910–918.
- Thiel, V., Herold, J., Schelle, B. & Siddell, S. G. (2001) *J. Virol.* **75**, 6676–6681.
- Sawicki, S. G. & Sawicki, D. L. (1998) *Adv. Exp. Med. Biol.* **440**, 215–219.
- Zúñiga, S., Sola, I., Alonso, S. & Enjuanes, L. (2004) *J. Virol.* **78**, 980–994.
- Gorbalenya, A. E., Koonin, E. V., Donchenko, A. P. & Blinov, V. M. (1989) *Nucleic Acids Res.* **17**, 4847–4861.
- Seybert, A., Hegyi, A., Siddell, S. G. & Ziebuhr, J. (2000) *RNA* **6**, 1056–1068.
- Ivanov, K. A., Thiel, V., Dobbe, J. C., van der Meer, Y., Snijder, E. J. & Ziebuhr, J. (2004) *J. Virol.* **78**, 5619–5632.
- Anand, K., Ziebuhr, J., Wadhvani, P., Mesters, J. R. & Hilgenfeld, R. (2003) *Science* **300**, 1763–1767.
- Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L., Guan, Y., Rozanov, M., Spaan, W. J. & Gorbalenya, A. E. (2003) *J. Mol. Biol.* **331**, 991–1004.
- Thiel, V., Herold, J., Schelle, B. & Siddell, S. G. (2001) *J. Gen. Virol.* **82**, 1273–1281.
- Laneve, P., Altieri, F., Fiori, M. E., Scaloni, A., Bozzoni, I. & Caffarelli, E. (2003) *J. Biol. Chem.* **278**, 13026–13032.
- Pan, T. & Uhlenbeck, O. C. (1992) *Biochemistry* **31**, 3887–3895.
- Bartlett, G. J., Porter, C. T., Borkakoti, N. & Thornton, J. M. (2002) *J. Mol. Biol.* **324**, 105–121.
- Hausmann, Y., Roman-Sosa, G., Thiel, H. J. & Rümenapf, T. (2004) *J. Virol.* **78**, 5507–5512.
- Gorbalenya, A. E. (2001) *Adv. Exp. Med. Biol.* **494**, 1–17.
- Snijder, E. J., den Boon, J. A., Bredenbeek, P. J., Horzinek, M. C., Rijnbrand, R. & Spaan, W. J. (1990) *Nucleic Acids Res.* **18**, 4535–4542.
- Pasternak, A. O., van den Born, E., Spaan, W. J. & Snijder, E. J. (2001) *EMBO J.* **20**, 7220–7228.
- Xu, H. Y., Lim, K. P., Shen, S. & Liu, D. X. (2001) *Virology* **288**, 212–222.